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Crystal Structure of a Complement Control Protein
that Regulates Both Pathways of Complement
Activation and Binds Heparan Sulfate Proteoglycans
rides, 1998). A better understanding of how CCPs carry
out their biological roles at the structural level is there-
fore of considerable interest.
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of VCP have 24, 33, 35, and 29 identical or conservatively
replaced residues (out of about 60) compared to the
equivalent four modules at the N terminus of the a chainSummary
of C4b-BP. VCP is the smallest and least complex of
the complement control proteins with no glycosylationVaccinia virus complement control protein (VCP) inhib-
or membrane attachment sites and only 244 aminoits both pathways of complement activation through
acids, making it an excellent candidate for structuralbinding the third and fourth components. A homolog
analysis.of mammalian regulators of complement activation,
VCP has been shown to inhibit the classical pathwayits ability to bind heparin endows VCP with additional
of complement activation, with greater potency thanactivities of significance to viral infectivity. The struc-
human C4b-BP, through its ability to bind C3 and C4ture of VCP reveals a highly extended molecule with
and act as a cofactor for factor I cleavage of C3b and
a putative heparin recognition site at its C-terminal
C4b (Kotwal, 1990, 1994; McKenzie et al., 1992). It has
end. A second cluster of positive charges provides a
also been shown to inhibit the alternative pathway
possibly overlapping binding site for both heparin and through the same mechanism, resulting in the cleavage
complement components. Experiments suggested by of C3b into iC3b, thereby preventing the formation of the
the structure indicate that VCP can bind heparin and alternative pathway C3 convertase (Sahu et al., 1998).
control complement simultaneously. This, the struc- Through this ability to block the host’s complement sys-
ture of any intact regulator of complement activation, tem, VCP has been demonstrated to be capable of pre-
along with attendant functional insights, will stimulate venting antibody-mediated virus neutralization (Isaacs
the design of new therapeutic inhibitors of com- et al., 1992). Therefore, VCP, secreted from virally in-
plement. fected cells, is believed to protect the host cell and
release viral progeny from host complement attack. In
Introduction addition, by blocking complement activation at multiple
sites, it reduces levels of C3a, C4a, and C5a proinflam-
Inappropriate or undesirable activation of the comple- matory chemotactic factors, resulting in reduced cellular
ment system is the cause of tissue destruction in a long influx and inflammation. Support for this comes from
list of clinical situations including ischemia-reperfusion in vivo experiments using BALB/c mice injected in the
injury, hyperacute rejection of xenogeneic transplants, footpad with cowpox virus (CPV) expressing or lacking
asthma, restenosis, systemic lupus erythematosus, Alz- the VCP homolog in CPV, termed inflammation modula-
heimer’s disease, and biomaterial incompatibility injury. tory protein (IMP, 93% identical to VCP) (Miller et al.,
1997). Results showed a significantly greater influx ofThe potential use of complement control proteins (CCPs)
inflammatory cells into the tissue upon infection withand derivatives as inhibitors of complement activation
CPV lacking IMP as compared to infection by CPV ex-in these conditions is an intensive area of research (Mak-
pressing IMP (Howard et al., 1998; Kotwal et al., 1998).
Recently, VCP was shown to possess the ability tok To whom correspondence should be addressed (e-mail: murthy@
bind heparin as well as heparan sulfate proteoglycansonyx.cmc.uab.edu).
(heparin-like molecules, HS) on the surface of human# Present address: Department of Medical Virology, University of
Cape Town, Cape Town, South Africa. endothelial cells. In this respect, VCP is more similar to
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Figure 1. Five Independent Molecules Are
Similar
(a) Stereo pair of superposed Ca traces of all
five crystallographically independent mole-
cules in the two crystal forms are shown. Mol-
ecule A in form I crystals is colored red, mole-
cule B, blue, and molecules C, D, and E in
form II crystals are colored magenta, cyan,
and yellow respectively. CCP domains are la-
beled mod1–mod4.
(b) A Ca trace of molecule A from Form I
crystals is shown in magenta in the same ori-
entation as in (a). Every 10th Ca has been col-
ored yellow and numbered. The N- and C-ter-
minal residues are shown in cyan and labeled.
serum complement control proteins factor H and C4b- Although the structure of b2-glycoprotein I (b2-GPI or
apolipoprotein-H), a molecule with four CCP modulesBP, both of which have been shown to bind heparin
(Hessing et al., 1990; Pangburn et al., 1991; Blom et al., has been reported (Bouma et al., 1999; Schwarzen-
bacher et al., 1999), b2-GPI is not a complement inhibitor.1999). Through this activity, VCP exhibits many proper-
ties that have not been demonstrated for other comple- Thus, to date there has been no three-dimensional struc-
ture available of a protein or protein fragment that isment control proteins. It has been shown that VCP is
taken up by mast cells (localizing in the heparin gran- able to regulate complement activation.
In every reported structure of fragments of CCP mod-ules), allowing for tissue retention, possibly increasing
its half-life in tissue. VCP has also been shown to bind ule containing proteins, each module folds into a com-
pact 6- to 8-stranded b structure that has a conformationheparin-like molecules lining the surface of endothelial
cells. In vivo studies have indicated that fluorescein iso- similar to that originally observed in the structure of fH16
(Barlow et al., 1991). The modules are connected bythiocyanate (FITC) labeled VCP, when injected intrave-
nously, becomes localized in the endothelium. This “linkers” of varying lengths.The relative orientations of
neighboring modules differ from one module-pair to an-property of VCP has been shown in vitro to reduce che-
motactic migration of leukocytes in the presence and other (Barlow et al., 1993; Casasnovas et al., 1999; Gabo-
riad et al., 2000; Henderson et al., 2000) quite radicallyabsence of the chemokine MIP-1a (Reynolds et al.,
2000). In addition, through this ability to bind heparan and in a manner that is not predictable from differences
in primary sequences. Nonetheless, bi-modular orienta-sulfate proteoglycans, VCP was able to inhibit antibody
binding to MHC class I molecules on human endothelial tional preferences have been used in building structures
containing three or more CCPs. Such models, conjec-cells (Smith et al., 2000). VCP has also been shown to
block interactions between pig aortic endothelial cells tured to represent the regulatorily competent forms,
have been used to fulfill a long felt need to provide a(PAECs) and naı¨ve neutrophils and natural killer cells,
preventing cell death (Al-Mohanna and Kowtal, 2001). three-dimensional context for functional and mutational
studies of RCA proteins. Examples include models forMoreover, cell culture studies demonstrate that VCP
blocks complement-mediated killing of PAECs by hu- the structures of VCP (Smith et al., 2000) and MCP (Lis-
zewski et al., 2000). Homology modeling has also beenman serum, in a dose-dependent manner. Thus, the
ability of VCP to bind heparin-like molecules plays many used, perhaps with greater validity, to develop C3dg
binding bimodular fragments of CR2 (Molina et al., 1995;physiologically interesting roles and therefore may have
a variety of applications. Nagar et al., 1998; Prodinger et al., 1998) based on those
of fH. However, in the absence of any structure of aStructures of fragments of MCP (two out of four CCP
modules [Casasnovas et al., 1999]) and fH (one [Barlow functional stretch of CCP modules, such models are
speculative.et al., 1991, 1992] or two [Barlow et al., 1993] out of 20
CCP modules) have been determined. Structures of two We report here the crystal structure, in two different
crystal forms, of VCP that is fully active both in comple-pairs of modules in VCP, modules 3 and 4 (VCP3,4,
[Wiles et al., 1997]) and VCP2,3 [Henderson et al., 2000]) ment inhibition and in binding heparin. This structure
offers a picture of the three-dimensional juxtapositionare also known. None of these fragments—removed
from the context of the rest of the protein—shows com- of the full set of CCP domains necessary for a well-
characterized complement inhibitory activity. Unlikeplement inhibition activity. There is compelling experi-
mental evidence, from work for example on CR1 (Krych studies of fragments, this structure is not susceptible
to the criticism that deletion of modules might haveet al., 1998) and VCP (Smith et al., 2000), that at least
three CCP modules are necessary for regulatory activity. destabilized the structures of the remaining modules
Structure of Vaccinia Complement Regulatory Protein
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Figure 2. Orientations of CCP Module Con-
taining Proteins Are Diverse
The four modules of VCP are shown in red
and labeled.
(a) The first CCP module of MCP (gold) is
superimposed over module 1 of VCP using
the b sheet residues in each to calculate the
transformation. Similarly module 2 of the so-
lution structure of VCP2,3 (rose) is superim-
posed over that of VCP2 and module 3 of the
solution structure of VCP3,4 (purple) superim-
posed over module 3 of VCP.
(b) The first CCP module of VCP is superim-
posed over module 1 of b2GPI (light blue).
Modules 1–4 in each are labeled. Not shown
is an additional membrane association do-
main beyond domain 4 in b2GPI.
and altered orientations at intermodular junctions. Anal- of mutagenesis experiments aimed at understanding the
structural basis of complement control.ysis of the distribution of surface charge on the molecule
and correlation of structural features with some new
and existing functional studies on CCPs suggests likely
Results and Discussion
locations for interaction of VCP with heparin, C3b, and
C4b. In addition, the presence of a putative heparin
Structure of VCP
binding site at one end of an elongated VCP might permit
In both the crystal forms of VCP that were analyzed, the
it to associate with negatively charged cell surfaces,
molecule has an elongated structure with no intramolec-
enabling it to mimic the function of other RCA family
ular contacts between nonsequential modules (Figure
proteins closely. The high level of sequence similarity
1). Packing of the two molecules (A and B) in the asym-
between VCP and the mammalian regulators of comple-
metric unit of form I crystals is head-to-tail, with CCP
ment activation (fH, MCP, DAF, CR1, and particularly
module 4 of each molecule making electrostatic and
C4b-BP) and to complement receptor type 2 (CR2)
van der Waals contacts with module 1 of the other;
means that this VCP structure will provide the richest
thus an approximately 2-fold rotation relates the two
and most reliable source of information yet available
molecules in the asymmetric unit. In form II crystals, on
for modeling other functional stretches of three-to-four
the other hand, the three molecules (C, D, and E) in the
CCPs by homology and for the design and interpretation
asymmetric unit are related by an approximate 3-fold
rotation, with translations moving molecules C and E by
roughly half their lengths along the axis of rotation such
that modules 3 and 4 of D interact with modules 1 and
2 of both C and E. Packing interactions within the asym-
metric units of both crystal forms do not show evidence
of specific multimerization of VCP molecules.
All five crystallographically independent molecules in
the two structures are highly similar in structure, as
reflected in root mean square (rms) deviations of 0.28,
0.67, 0.68, and 0.69 A˚, between Ca atoms in the b strands
of molecule A and those of B, C, D, and E (Figure 1),
respectively. At the module level, a very similar overall
fold has been observed within several structures of RCA
members and their fragments (Barlow et al., 1991, 1992,
1993; Wiles et al., 1997; Casasnovas et al., 1999; Gabo-
riad et al., 2000). The originally observed 6 b strand
topology is closely emulated by all CCP modules of
both copies of VCP within the asymmetric unit of form
Figure 3. Electrostatic Attributes of VCP
I crystals. In regions where residues could be located
Domain 1 is at the top and domain 4 at the bottom in all panels. in electron density maps, all CCP modules comprising
(a) Electrostatic potential mapped on to the molecular surface of
each of the three molecules within the asymmetric unitmolecule A of form I crystals. Dark blue represents 10.2 electrons
of form II crystals also conform to this topology. Moduleper A˚ and red represents 24.3 electrons per A˚.
(b) Expanded views of the two positive patches between domains 1 is remarkable for its prominent “hypervariable” loop
1 and 2 (top) and domain 4 (bottom). The top half of the panel is in of ten residues (Lys14–Ala23, compared to two, four,
approximately the same orientation as (a); the bottom panel repre- and five residues in modules 2, 3, and 4, respectively)
sents a view as seen from the bottom of (a) looking up at module projecting laterally from VCP close to the N-terminal tip
4. Lys and Arg residues contributing to each patch are labeled.
of the molecule. Module 1 also has an unusual insertion(c) Representation of the 62 kT contour of the potential field around
(Gln42, Lys43) that forms a prominent b bulge close tothe molecule calculated and displayed by GRASP using program
defaults for all parameters. a carbon trace is shown in yellow. the interface with module 2. Module 2 has a five residue
Cell
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Figure 4. Putative C3/C4 Binding Residues
in VCP
(a) Alignment of the sequences of VCP and
MCP in regions identified as potential C3/C4
binding sites in the latter are shown. The three
sets of residues in MCP shown to decrease
C4b binding (red) and C3b binding (magenta
and yellow) when mutated are shown. VCP
residues in positions corresponding to those
in MCP, which, from an examination of the
VCP structure, appear to be accessible, are
also shown in matching colors.
(b) Spatial relation of C3/C4 binding to hepa-
rin binding in VCP. The positive patch be-
tween modules 1 and 2 is shown with contrib-
uting basic residues labeled. Side chains of
residues of putative importance for C3b and
C4b binding by VCP are shown as CPK
spheres on an a carbon trace (light blue) of
VCP. Color coding is the same as in (a). Sev-
eral residues are labeled. Heparin hexa-
sacchride (carbon, brown; oxygen, red; nitro-
gen, blue; and sulfur, yellow) derived from the
complex with acidic FGF is also shown below
with the four lysine residues (cyan) that mod-
eling suggests are likely ligands.
insertion (Leu109–Ser114) that forms a long loop close intact VCP in the crystal with solution studies on VCP
fragments (Figure 2a). The angles between modules 3to the interface with module 1.
As suggested by the rms deviations, the relative orien- and 4 of the NMR structure of VCP3,4 (tilt 5 678, twist 5
818, and skew 5 78; see Wiles et al., 1997 for a definitiontations of each of the four modules are also remarkably
similar among all five molecules despite their being crys- of these angles), are comparable to those seen in the
crystal structure (tilt 5 998, twist 5 748, and skew 5 2208).tallographically independent (Figure 1). This suggests
that crystal packing interactions are not responsible for The 2–3 intermodular angles within the NMR structure
of VCP2,3, on the other hand, are dissimilar to those inthe conformation observed, but rather that a strongly
preferred conformation of VCP exists in solution under the crystal structure of intact VCP (Figure 2a). Moreover
z281 A˚2 of surface is buried between modules 2 and 3the conditions used to grow the crystals. The “tilt” (i.e.,
the rotation required to align the z-axis of the inertia in the crystal, while the junction between these two
modules is not extensive in the VCP2,3 fragment (Kirki-tensor of each module with its neighbor) angles between
the long axes of the modules are 608, 638, and 998 at tadze et al., 1999) and NMR indicates that this pair is
flexible on a 1027 to 1028 time scale (Henderson et al.,the 1–2, 2–3, and 3–4 module junctions, respectively.
However, the tilts between adjacent pairs of modules 2000). It is noticeable that there are significant differ-
ences in the structure of module 2 between intact andare in almost diametrically opposite directions so that
module 3 is tilted by only 108 relative to module 1 and truncated forms of VCP, while modules 3 and 4 show
only small differences (Figure 2a). The lack of module 1module 4 is tilted by 368 relative to module 2. Thus, the
molecule has an extended and approximately linear part might destabilize module 2 in VCP2,3 and hence the 2,3
junction; for example the Leu109–Ser114 insertion inconsisting of modules 1–3, then a kink between modules
1–3 and module 4. Atomic interactions at the 1–2 inter- module 2 is a mobile loop in VCP2,3, but has moved by
some 15 A˚ in the crystal structure and contacts theface in VCP are between mostly hydrophilic residues
while those at the 2–3 interface are mixed and those at Gln42,Lys43 insertion of module 1. Modules 2 and 3
might also stabilize each other, but to a lesser extent,the 3–4 interface are predominantly hydrophobic. The
1–2 module interface buries 454 A˚2 of accessible surface which could explain the smaller differences between the
arrangement of modules 2 and 4 in intact VCP comparedcompared to 281 and 408 A˚2, respectively, for the 2–3
and 3–4 interfaces. to the VCP3,4 fragment. It is clear from these compari-
sons that the structure of VCP reported here, that of anFigure 2a superimposes the structures of VCP and
MCP1,2 (Casasnovas et al., 1999). The arrangement of intact complement control protein, represents a signifi-
cant advance over previous structural studies based onthe N-terminal MCP modules differ from that in VCP,
providing another example of the significant variation in fragments—its validity does not rely on the assumption
that CCP modules are structurally independent of theintermodular orientations among this family of proteins.
This study also allows comparison of the structure of remainder of the protein. This structure may therefore
Structure of Vaccinia Complement Regulatory Protein
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be considered the most reliable basis yet for the design
of mutagenesis experiments and homology modeling
exercises.
A striking feature of each VCP molecule is the charge
distribution on the four domains. A concentration of
basic residues in modules 1 and 4 makes them highly
positively charged with a number of Lys and Arg resi-
dues contributing to the charge density (Figures 3a and
3b). Most of the residues with carboxylic acid side
chains are clustered in modules 2 and 3 with those two
modules carrying a net negative charge. This charge
distribution, taken together with the highly extended
shape of VCP revealed in this study, produces a dis-
tinctly asymmetric distribution of the electrostatic field Figure 5. Stereo View of Interaction of VCP with Heparin
around each molecule, with module 4 being surrounded
A Ca trace of residues 213–242 of VCP is shown in orange. Carbohy-
by an intense positive field that extends significantly drate is shown with carbons colored gray; oxygen, red; nitrogen,
beyond its van der Waals footprint, module 1 having a blue; and sulfur, yellow. Side chains of the four basic residues of
more textured although mostly positive field around it acidic and basic FGF and VCP that were superimposed are shown
in red, magenta, and cyan, respectively. VCP side chains are labeled.and the middle two domains being surrounded by a
The figure was composed using a rigid body transformation of VCPpredominantly negative field (Figure 3c).
main chain on to the basic FGF heparin binding segment. The side
chains of the Lys residues in VCP have been rotated to point toward
the heparin fragment. The side chain of Lys 214 is beyond hydrogen
Interaction of VCP with C3 and C4 bonding distance from heparin as currently modeled. Main chain
A pervasive theme that runs through descriptions of movements of 1–2 A˚ will be required to bring its side chain within
interacting distance.molecular interactions between complement regulatory
factors fH, CR1, and CR2 with C3 is the involvement
of carboxyl residues on C3 and basic residues on the
regulatory factors. The structure of C3d (Nagar et al., interaction with C3 can take place through either module
1998), and subsequent mutational analysis (Clemenza 1 and 2 or module 4. However, experiments with trun-
and Isenman, 2000) have identified glutamyl residues cated versions have shown that VCP that has lost mod-
(mature C3 numbering) 1008, 1010, 1131, and 1137 as ule 1 is incapable of complement inhibition (Smith et al.,
well as Asp 1134 as providing contacts to CR2. Residues 2000), while a close relative of VCP, the monkey pox
Glu736 and Glu737 have been identified as contributing virus (MPV) homolog, without a large portion of module
major contacts for interaction of C3(H2O) with fB and 4, is still competent (Smith et al., 2000). Thus the positive
CR1 (Oran and Isenman, 1999). Mutagenesis of residues patch, to which Arg 7, Lys 12, Lys 14, Arg 40, Lys 41,
within C3 (Oran and Isenman, 1999), use of blocking Lys 43, Lys 50, Lys 64, Arg 65, and Arg 66 contribute
antibodies (Alsenz et al., 1990), and synthetic mimetics (Figure 3b), which straddles modules 1 and 2, might be
(Fishelson, 1991) have been used to show that residues one point of contact between VCP and C3/C4 responsi-
Glu-744 and Glu-747 make major contributions to bind- ble for its complement regulatory activity.
ing of fH by C3(H2O). Additional putative sites on VCP for interaction with
Conversely, mutagenesis experiments that have ei- C3b/C4b are suggested by comparison with other com-
ther reduced the negative charge or increased the posi- plement control proteins for which extensive mutagene-
tive charge in CR1 by substitution of acidic or basic sis data are available. A recent study employing syn-
residues, respectively, near putative interaction sites thetic peptides, mutagenesis, and epitope mapping of
have increased binding to C3 (Krych et al., 1998). Simi- MCP is one of the most comprehensive (Liszewski et
larly, several basic residues between CCP modules 1 al., 2000). An alanine-scan of MCP from residues 94–103
and 2 in CR2 have been identified as possible ligands (Figure 4a) proved particularly interesting. The mutations
for C3d (Prodinger et al., 1998) and a cluster of positively Y97A, Y98A, L99A, and E103A each abolished cofactor
charged residues at the interface between C4b-BP mod- activity for C4b but not binding of C4b, while N94A,
ules 1 and 2 have been shown to be crucial for C4b E95A, G96A, and E102A decreased both C4b binding
binding (Blom et al., 1999). Analogous observations, and cofactor activity (C3b binding was affected only by
based on conserved sequence motifs, have also been E102A). The equivalent residues in VCP are also 94–103,
made for fH (Soames et al., 1996). It appears, therefore, are close in sequence (Figure 4a), and lie in module 2
that interaction of positively charged portions of com- near the interface with module 3. In VCP, the conserved
plement regulators CR1, CR2, C4b-BP, and fH with neg- Tyr97 and Leu99 are buried and substitution with alanine
atively charged regions on C3/C4 makes a significant, is likely to be structurally disruptive, while Gly96 is in a
if not a dominant, contribution to their interaction. turn and probably also of structural importance; the side
The close functional and structural resemblance of chains of Asn94, Ser95 (Glu in MCP), His98 (Tyr in MCP),
VCP to other complement control proteins strongly sug- Glu102, and Ser103 (Glu in MCP), on the other hand,
gests that its interactions with C3b would also involve are surface exposed. Thus, by homology with the VCP
patches of positive charge, although other regions are structure, it is likely that residues 94, 95, 98, 102, and
also likely to be involved. Charge distribution on the 103 of MCP (Figure 4a, red) are involved directly in inter-
molecular contacts, and that Asn94, Glu95, and Glu102VCP molecule (Figures 3a and 3b) suggests that an ionic
Cell
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Figure 6. Simultaneous Heparin/Heparan Binding and Hemolysis Inhibition by VCP
(a) Results of hemolysis assays performed on serially diluted samples of rVCP each containing 0.01, 0.1, and 1.0 mg of soluble heparan sulfate
with an average molecular weight of 7500 (filled circles, open triangles, and open circles, respectively) are compared to the sample without
heparan sulfate (control, shown as filled squares). The degree of hemolysis inhibition caused by heparan sulfate alone is shown as asterisks.
(b) The results of a hemolysis assay performed on rVCP bound to heparin sepharose beads are compared to the sample without heparin
sepharose (control shown as squares). The results of a hemolysis assay performed on material that did not bind to the heparin sepharose
beads (supernatant) are shown as triangles.
(c) Coomassie blue stained SDS-PAGE shows (1) 3.0 mg of rVCP, (2) rVCP that was bound to the heparin sepharose beads after the hemolysis
assay shown above, and (3) rVCP that was contained within the supernatants after the hemolysis assay shown above. The material in lane 3
probably represents the fraction of rVCP that was incompetent in binding due to misfolding.
directly contact C4b. It is reasonable to propose that BP, CR2, MCP, and CR1, a number of sites on VCP
probably interact with C3b and C4b. The structure ofAsn94, His 98, and Glu102 (Figures 4a and 4b, red) play
a similar role in VCP. The same study (Liszewski et al., VCP allows these sites to be visualized to allow identifi-
cation of surface-exposed residues likely to be involved2000) indicated that the region 191–196 (Figure 4a) of
MCP appeared important for C3b binding; thus individ- directly in contacts. These are summarized in Figure 4b
and are good candidates for future mutagenesis studiesual substitutions of K193, R195, and F196 by alanine
interfered with both C3b binding and cofactor activity of VCP. The structure also allows the spatial relationship
of these putative binding sites, as well as their relationfor C3b. In VCP, the equivalent region is 184–189 (Figure
4a) and lies at the C terminus of module 3 with Lys186 to the positive patch that is between modules 1 and 2,
to be visualized (Figure 4b).and His189 solvent exposed and is probably not of fun-
damental structural importance. Thus, by homology with
VCP it is likely that Lys193 and Phe196 of MCP (Figure Heparin Binding and Hemolysis Inhibition by VCP
Among the mammalian proteins shown to have comple-4a, magenta) contact C3b; again, it is reasonable to
propose that Lys186 and His189 of VCP (Figures 4a and ment control ability, only the serum proteins C4b-BP
and fH have heparin binding activity. Binding sites for4b, magenta) play a similar role. Finally, in MCP, residues
in the region 206–212 (Figure 4a) appeared to be in- heparin on CCP modules 1 and 2 on the a chain of C4b-
BP (Blom et al., 1999; Hessing et al., 1990) and on CCPvolved in C3b binding since the mutations G207A,
F208A, K210A, K211A, and F212A each significantly de- modules 7, 20, and 13 for fH (Sharma and Pangburn,
1996; Blackmore et al., 1998) have been identified. VCPgrade affinity for C3b (but not C4b). In VCP, these resi-
dues lie within the sequence 199–205 (Figure 4a),which has been shown to possess a strong heparin binding
ability and experiments have indicated the possibleincludes the hypervariable bulge of module 4 with
Phe201 and Arg203 prominent on the surface. By homol- presence of two heparin binding sites on modules 1 and
4, respectively (Reynolds et al., 2000; Smith et al., 2000).ogy with the structure of VCP, Phe208 and Lys210 of
MCP (Figure 4, yellow) are likely to be contact points The structure of VCP confirms that there are two spa-
tially distinct putative heparin binding sites in the mole-for C3b. Although it is not unreasonable to invoke
Phe201 and Arg203 (Figures 4a and 4b, yellow) as C3b cule. VCP, in the crystal structures, appears to be a long
molecule with large positively charged domains at itsbinding residues in VCP, most of this module, including
residues 208 and 210, is missing from its MPV homolog two ends (Figures 3a and 3b); a large patch of positive
charge is located on domain 4, while a second largeand therefore does not appear to be pivotal for function.
In summary, by analogy with its close relatives, C4b- positive patch straddles domains 1 and 2. Heparin pro-
Structure of Vaccinia Complement Regulatory Protein
307
Table 1. Structure Determination and Refinement
Form I (Eu MAD) Form II (Au MAD)
Native Remote Peak Edge Native Remote Peak Edge
Diffraction Data
Wavelength (A˚) 1.03753 1.771758 1.774938 1.776156 1.03753 1.03753 1.039443 1.040067
Resolution (A˚) 2.2 2.5 2.5 2.5 2.6 2.8 2.8 2.8
Completeness1 (%) 93 (82) 96 (80) 90 (75) 95 (81) 96 (81) 91 (69) 88 (71) 92 (72)
Rsym2 0.050 0.036 0.051 0.068 0.039 0.053 0.057 0.048
,I/sI. 40.7 49.7 33.9 37.2 40.6 32.9 31.2 32.1
Phasing
,Figure of merit. MAD3 0.65 (1.89) 0.62 (1.65)
,Figure of merit. DM3 0.78 (2.53) 0.80 (2.13)
Refinement
Resolution (A˚) 8–2.2 8–2.64
Number of reflections 39322 72300
(F . 2sF)
Rcryst 0.198 0.204
Rfree4 0.234 (4207) 0.236 (8035)
Geometry
rms deviations in:
Bond length (A˚) 0.006 0.007
Bond Angle (Degrees) 1.1 1.4
B values between 2.9 3.3
bonded atoms
1 Completeness in the outer shell in parentheses.
2 Rsym 5 ouI 2 ,I./oI where I is the observed intensity and ,I. the average of multiple observations.
3 Phasing power (rms FH/RMS e ) in parentheses.
4 Number of reflections in parentheses.
tein interactions are dominated by charge interactions binding complement spread throughout the remainder
of this extended molecule, it might be expected that C3b/between negatively charged groups on heparin and pos-
itively charged groups on proteins. Heparin binding se- C4b interactions and heparin binding are not mutually
exclusive. Participation of common residues in heparinquence motifs in proteins consisting of suitably spaced
Lys and Arg residues have been proposed (Margalit et binding and complement inhibition in VCP is not sup-
ported by the observation that VCP is able to inhibital., 1993) and such motifs have been identified in VCP
(Smith et al., 2000). Structures of acidic (DiGabriele et hemolysis of sensitized sheep red blood cells and bind
heparin simultaneously (Figure 6). Addition of varyingal., 1998; Schlessinger et al., 2000) and basic (Faham et
al., 1996) fibroblast growth factors (FGFs) complexed amounts of soluble HS to a hemolysis assay containing
VCP had no effect on the protein’s ability to inhibit hemo-with heparin have offered insights into details of binding
of heparin by proteins. Modeling of heparin binding to lysis (Figure 6a). A similar experiment employing heparin
sepharose beads, used to carry VCP into the hemolysisVCP employing FGF as template and using Insight II
(Biosym-Technologies, 2000) shows that a carbon assay, revealed that VCP can still inhibit complement
activation while remaining bound to insoluble heparin,atoms of a quartet of Lys residues 214, 216, 220, and
241 in a flexible region of module 4 could be superim- although to a much lesser extent (Figure 6b). The reac-
tion mixture was further examined after the assay wasposed on corresponding atoms of four basic residues,
Lys113, Arg119, Arg112, and Lys 128 in acidic FGF, performed in order to determine whether VCP inhibits
hemolysis while bound to heparin, or is pulled off by C3which make major interactions with heparin in the com-
plex (DiGabriele et al., 1998; Schlessinger et al., 2000), and C4 during the reaction. Figure 6c clearly demon-
strates that the hemolysis-inhibiting activity could bewith an rms deviation of 2 A˚. All the ligands in module
4 are either end residues of b strands or are in flexible attributed to VCP that remained bound to the heparin
sepharose beads and was not detached from the beadsloops between strands (Figure 5). Similarly, residues
Lys 64, Arg 65, and Arg 66 in module 1 and the linker in the process. These experiments imply that the protein,
in addition to its ability to strongly inhibit complementconnecting modules 1 and 2 can be superimposed on
residues Lys 122, Lys 118, and Arg 119 of FGF with a activation while in soluble form, may also inhibit comple-
ment while bound to heparan sulfate proteoglycans lin-deviation of 1 A˚. These two putative heparin binding
regions are separated by about 80 A˚. Figure 5 shows a ing the endothelial cell layer. VCP would therefore be
able to protect the infected host cell, and neighboringstereo view of the model for the site at the tip of module
4. It is significant that the model for VCP interactions with cells, from not only host complement attack, but also
antibody binding and cell death caused by natural killerheparin resembles that in the FGFs closely, an unrelated
protein, indicating heparin-protein recognition mode of cells.
Complement activation either through the classical orwide applicability.
Since VCP is an extended molecule, and given the the alternative pathway occurs on cell surfaces, which
in addition to identifying cells as “foreign”, limits theprobable location of a heparin binding site at the ex-
treme C-terminal end and putative regions involved in possibility of a “runaway” reaction that could result in
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deleterious host tissue destruction (Hughes-Jones, beads or to cell surfaces through its heparin/C4b bind-
1986; Pangburn, 1986). Although experiments with solu- ing site would be incapable of participating in inhibiting
ble versions of MCP, DAF, and CR1 have shown that all hemolysis because C3/C4 binding sites would be
of them are capable of displaying regulatory activity in blocked. Furthermore, VCP bound to beads through
solution (Reid and Day, 1989), in their native state they module 4 would be unavailable to associate with cell
are associated with the cell surface, presumably be- surfaces, thus making it less efficient in inhibiting hemo-
cause such association would be an efficient way of lysis. A geometric arrangement of surface association
regulating surface-bound components of the pathway sites with respect to functional sites similarly to that in
such as the C3 and C5 convertases. Different strategies VCP has been observed in the structure of b2GPI (Bouma
for surface association have been adopted by different et al., 1999; Schwarzenbacher et al., 1999), which al-
regulators. MCP (Liszewski et al., 1991), CR1, and CR2 though not possessing complement regulatory activity,
(Ahearn and Fearon, 1989) associate with cell surfaces is made up of CCPs and binds to cell membranes. The
through transmembrane regions. On the other hand, binding site for anionic phospholipids in b2GPI, com-
DAF associates with cell surfaces through a glycosyl posed of a number of basic and several hydrophobic
phospatidyl inositol membrane anchor (Coyne et al., residues, is at the tip of the fifth module of that protein
1992). However, C4b-BP, fH, and VCP, among proteins with antibody binding sites distributed over the re-
shown to possess complement regulatory ability, are maining four modules.
not bound to surfaces in their native state and all of In conclusion, the structure of VCP displays several
them are now known to bind heparin. Both the serum interesting features that are of relevance to its comple-
complement regulators fH and C4b-BP, as well as VCP, ment regulation and heparin binding activities. This
probably bind to cell surfaces for the same reason that structure of a protein that regulates complement activa-
other CCPs are associated with cell surfaces; in order tion provides a structural framework for interpretation of
to regulate cell surface associated components more existing mutational and functional data on homologous
efficiently. Such a role for heparin binding by C4b-BP human complement regulatory proteins. This is exempli-
has indeed, been explored extensively (Meri and Pang- fied by comparison of VCP with MCP, which allows ratio-
burn, 1994; Sharma and Pangburn, 1996; Blom et al., nalization of previously performed alanine-scan muta-
1999). genesis of MCP, indicating residues that make direct
In factor H there are three heparin binding sites on interactions as opposed to those that are structurally
CCP modules 7, 13, and 20 (Sharma and Pangburn, important. The structure will also provide a platform for
1996). It has been reported that binding of heparin in- design of future experiments for a detailed dissection
creases binding of fH to C3b, enhancing both its decay of structure-function relations of VCP and other RCA
acceleration and cofactor activities (Meri and Pangburn, proteins. The data on C3b and C4b binding to MCP
1994). C4b-BP is a bigger and more complex protein indicate that probable contact points for interaction of
than VCP, with seven identical, extended a chains, each C3b and C4b with VCP are located primarily on the first
with eight CCP modules and a single b chain with three three modules. Although there are two potential heparin
CCP modules (Hillcarp and Dahlback, 1988). Mutational binding sites, experiments with truncated versions of
and proteolytic fragmentation studies have identified the protein and the observation that heparin binding and
several basic residues between the first two modules complement inhibition by VCP are not mutually exclu-
of the a chain, including Arg 39, Arg 64, and Arg 66, to sive, suggests that the site on module 4 is likely to be
be important for both heparin binding and C4b binding the primary binding site for heparin. These observations,
(Blom et al., 1999). The same study provided an explana- along with the electrostatic attributes of VCP, lead to a
tion for the multivalency of C4b-BP by suggesting that plausible model for cell-surface association of VCP that
some of heparin/C4b binding sites on the eight a chains would make it functionally similar to membrane associ-
would help C4b-BP bind to heparin on cell surfaces
ated regulators such as MCP, DAF, and CR1, although
while the rest would be able to interact with surface-
the mechanism of surface association is different. Fi-
deposited C4b in the vicinity. Thus, it appears plausible
nally, these findings will underpin the design of thera-to suggest that VCP might use heparin binding as a
peutic regulators of complement. The vaccinia virus ap-means of cell-surface association. Like its very close
pears to have arrived at an elegant solution to thehomolog, C4b-BP, VCP has a site between modules 1
problem of how to encapsulate an efficient strategy forand 2 that is likely a dual heparin and C4b binding site;
surface-targeted complement inhibition in a small, solu-however, VCP also has a second putative heparin bind-
ble, unglycosylated protein. The availability of this struc-ing site on module 4. Since it is small and monomeric,
ture provides the opportunity for further engineering toVCP could not carry out its function efficiently if binding
produce a more potent inhibitor of use in the clinic.to heparin occluded its complement interacting sur-
faces; this would explain the introduction, through a
process of molecular evolution, of the additional heparin Experimental Procedures
binding site on module 4. The stronger and more exten-
Purification of VCPsive electrostatic field that surrounds module 4 would
The cloning of VCP in the Pichia pastoris yeast expression systemalso be instrumental in orienting and driving the mole-
(Invitrogen) was described previously (Smith et al., 2000). Two milli-cule to bring about rapid surface association through
liters of buffered glycerol-complex medium (BMGY) was inoculated
the heparin binding site on this module. The decrease and grown at 308C overnight. This starter culture was then used to
in hemolysis activity, depicted in Figure 6b, for VCP inoculate two liters of BMGY contained within two large, four liter
bound to sepharose heparin beads compared to free flasks. The cultures were then grown at 308C for two days with
vigorous shaking. The cells were then harvested by centrifuging forVCP also supports this notion. VCP that is bound to
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30 min at 3500 rpm. After resuspending the cells in two liters of 2 s Fobs, a lower resolution of 8 A˚ and a higher resolution of 2.2 A˚
and 2.64 A˚, respectively, for the two crystal forms. The refinementsbuffered methanol-complex medium (BMMY) containing 4% metha-
nol, the cells were again incubated for two days with vigorous shak- were monitored throughout using free R values calculated on 10%
of the reflections, in each case chosen randomly to span the useding. The VCP-containing media was then collected after centrifuging
at 12,000 rpm for 1 hr. The two liters of media were then concen- resolution range. The terminal Arg residue is not visible in density
maps in any of the five molecules. All atoms of all other residuestrated to 50 ml using a 300 ml Amicon stirred-cell (with 10 kDa
molecular weight cut-off). Half of the media was then purified using (1–243) are present in both molecules of the asymmetric unit of form
I crystals; however, residues 43–45, 110, 209, and 227 in moleculethree 5 ml HiTrap heparin columns (Pharmacia) linked in series, as
to make one large 15 ml column. After passing the media through A have high B factors as do residues 209 and 227 in molecule B.
All three molecules in the asymmetric unit of form II crystals haveat a rate of 1 ml/min, the column was then washed with 30 ml of
100 mM NaCl, and the protein eluted with 15 ml NaCl ranging from residues that could not be located in maps: 4–7, 14–21, 23–24, 54,
58, 75, 111, and 207 in molecule C, residues 54, 58, 75, 111, 126,250 mM to 550 mM. The fractions were then visualized by SDS-PAGE
with Coomassie blue staining. This was repeated for the second half 202, 217–219, 220, 222, and 223 in molecule D, and residues 53,
54, 58, 75, 111, 126, 159, 160, 162, 184, 186, 202, and 217 in moleculeof the media and fractions containing the most highly pure rVCP
were pooled, concentrated using a 50 ml Amicon stirred-cell, and E. No residues are in disallowed regions of the Ramachandran map;
some geometric statistics are given in Table 1. Figure 1 was madesuperconcentrated and desalted using several 2 ml Millipore Centri-
con centrifugal filters. Protein concentrations were predicted using using Insight II (Biosym-Technologies, 2000), Figures 2, 3, and 4
using GRASP (Nicholls et al., 1991), and Figure 5 using RIBBONSa BioRad protein estimation kit, and the specific activity of the
samples was determined by hemolysis assay. (Carson, 1987). Atomic coordinates have been deposited in the Pro-
tein Data Bank with ID codes 1G40 (form I) and 1G44 (form II).
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